Teva Pharmaceutical Industries (TEVA) EBIAT: 2009-2025
Historic EBIAT for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $434.0 million.
- Teva Pharmaceutical Industries' EBIAT rose 199.31% to $434.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $662.0 million, marking a year-over-year increase of 152.41%. This contributed to the annual value of -$2.0 billion for FY2024, which is 218.54% down from last year.
- Per Teva Pharmaceutical Industries' latest filing, its EBIAT stood at $434.0 million for Q3 2025, which was up 53.36% from $283.0 million recorded in Q2 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' EBIAT peaked at $467.0 million during Q4 2023, and registered a low of -$1.3 billion during Q4 2022.
- For the 3-year period, Teva Pharmaceutical Industries' EBIAT averaged around -$153.0 million, with its median value being -$253.0 million (2023).
- In the last 5 years, Teva Pharmaceutical Industries' EBIAT slumped by 1,236.90% in 2022 and then surged by 199.31% in 2025.
- Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' EBIAT stood at -$152.0 million in 2021, then crashed by 776.97% to -$1.3 billion in 2022, then skyrocketed by 135.03% to $467.0 million in 2023, then slumped by 158.89% to -$275.0 million in 2024, then surged by 199.31% to $434.0 million in 2025.
- Its last three reported values are $434.0 million in Q3 2025, $283.0 million for Q2 2025, and $220.0 million during Q1 2025.